Cost modelling incorporating procalcitonin for the risk stratification of febrile infants ≤60 days old
Paediatrics & Child Health · 04.05.2023 · 28 (2) · 84-90
DOI: 10.1093/pch/pxac083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Paediatrics & Child Health, online erschienen am 26.12.2022. Verfasst von Zachary Dionisopoulos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Emergency Medicine, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, …. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
Procalcitonin testing is recommended to discriminate febrile young infants at risk of serious bacterial infections (SBI). However, this test is not available in many clinical settings, limited largely by cost. This study sought to evaluate contemporary real-world costs associated with the usual care of febrile young infants, and estimate impact on clinical trajectory and costs when incorporating procalcitonin testing.
Methods
We assessed hospital-level door-to-discharge costs of all well-appearing febrile infants aged ≤60 days, evaluated at a tertiary paediatric hospital between April/2016 and March/2019. Emergency Department and inpatient expense data for usual care were obtained from the institutional general ledger, validated by the provincial Ministry of Health. These costs were then incorporated into a probabilistic model of risk stratification for an equivalent simulated cohort, with the addition of procalcitonin.
Results
During the 3-year study period, 1168 index visits were included for analysis. Real-world median costs-per-infant were the following: $3266 (IQR $2468 to $4317, n=93) for hospitalized infants with SBIs; $2476 (IQR $1974 to $3236, n=530) for hospitalized infants without SBIs; $323 (IQR $286 to $393, n=538) for discharged infants without SBIs; and, $3879 (IQR $3263 to $5297, n=7) for discharged infants subsequently hospitalized for missed SBIs. Overall median cost-per-infant of usual care was $1555 (IQR $1244 to $2025), compared to a modelled cost of $1389 (IQR $1118 to $1797) with the addition of procalcitonin (10.7% overall cost savings; $1,816,733 versus $1,622,483). Under pessimistic and optimistic model assumptions, savings were 5.9% and 14.9%, respectively.
Conclusions
Usual care of febrile young infants is variable and resource intensive. Increased access to procalcitonin testing could improve risk stratification at lower overall costs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Emergency Medicine, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Economics, McGill University, Montreal, Quebec, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- McGill University Health Centre, Montreal, Quebec, Canada.
ORCID-Profile: Brett Burstein
Zitieren
APA
Dionisopoulos, Z., Strumpf, E., Anderson, G., Guigui, A., & Burstein, B. (2023). Cost modelling incorporating procalcitonin for the risk stratification of febrile infants ≤60 days old. Paediatrics & Child Health, 28(2), 84-90. https://doi.org/10.1093/pch/pxac083
Vancouver
Dionisopoulos Z, Strumpf E, Anderson G, Guigui A, Burstein B. Cost modelling incorporating procalcitonin for the risk stratification of febrile infants ≤60 days old. Paediatrics & Child Health. 2023;28(2):84-90. doi:10.1093/pch/pxac083
BibTeX
@article{Dionisopoulos2023,
author = {Dionisopoulos, Zachary and Strumpf, Erin and Anderson, Gregory and Guigui, Andre and Burstein, Brett},
title = {Cost modelling incorporating procalcitonin for the risk stratification of febrile infants ≤60 days old},
journal = {Paediatrics & Child Health},
year = {2023},
volume = {28},
number = {2},
pages = {84--90},
doi = {10.1093/pch/pxac083}
}
EUVIMED